Conjugated Monoclonal Antibodies Global Market By Product Type, By Application, By Payload Type, Regional Outlook, and Forecast 2024-2033 | Pfizer Inc., AbbVie Inc., Bayer AG, AstraZeneca PLC, Novartis AG

Spread the love

Overview and Scope
Conjugated monoclonal antibodies refer to a compound formed from a monoclonal antibody that has been chemically coupled to a medication. The monoclonal antibody binds to particular proteins or receptors that are present on particular cell types, such as cancer cells. The associated medicine enters these cells, kills them, and leaves the rest of the cells alone.

Sizing and Forecast
The conjugated monoclonal antibodies market size has grown strongly in recent years. It will grow from $10.9 billion in 2023 to $11.48 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to increasing prevalence of cancer, expansion of the private healthcare sector, government support, growing patient population.

The conjugated monoclonal antibodies market size is expected to see strongly grown in the next few years. It will grow to $14.64 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increased access to healthcare, growing demand for minimally invasive procedures, immunotherapeutic combinations, expanding healthcare access, expanding indications. Major trends in the forecast period include advances in drug delivery, biomarker-driven development, next-generation conjugates, patient-centric care.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/conjugated-monoclonal-antibodie-global-market-report

Segmentation & Regional Insights
The conjugated monoclonal antibodies market covered in this report is segmented –
1) By Drugs: Adcetris, Kadcyla
2) By Technology: Cleavable Linker, Non-cleavable Linker
3) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumour, Other Applications

North America was the largest region in the conjugated monoclonal antibody market in 2023. The Middle East is expected to be the fastest growing region in the global conjugated monoclonal antibodies market share during the forecast period. The regions covered in the conjugated monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3424&type=smp

Major Driver Impacting Market Growth
The increasing popularity and therapeutic potential of conjugated monoclonal antibodies, especially antibody-drug conjugates, is expected to drive the conjugated monoclonal antibodies market demand over the forecast period. Antibody-drug conjugates (ADCs), a class of therapeutics consisting of monoclonal antibodies (MAbs) clubbed with highly potent cytotoxic drugs through a linker to kill the antigen-expressing tumour cells, are predominantly used in the treatment of cancer. In the last three to four years, the U.S. Food and Drug Administration has approved only three antibody-drug conjugates, indicating that the increased number of approvals is directly proportional to the use of conjugated monoclonal antibodies, mainly in the field of cancer, which in turn aids in the growth of the conjugated monoclonal antibodies market.

Key Industry Players
Major companies operating in the conjugated monoclonal antibodies market include Pfizer Inc., F. Hoffmann-La Roche AG, Bristol -Myers Squibb, Merck & Co. Inc., Immunomedics Inc., Takeda Pharmaceuticals Industries Ltd., Daiichi Sankyo Company Limited, Actinium Pharmaceutical, Nordic Nanovector Inc., Spectrum Pharmaceuticals Inc., AbbVie Inc., Bayer AG, AstraZeneca plc, Novartis AG, Amgen, Celgene, Genentech, Emergent BioSolutions, Genzyme, Incyte Corporation, Kite Pharma, MorphoSys AG, Regeneron Pharmaceuticals, Seattle Genetics

The conjugated monoclonal antibodies market report table of contents includes:
1. Executive Summary